CMS Wistrand advises Chordate Medical Holding AB (publ) in connection with the company's rights issue
13 Feb 2025
Sweden
1 min read
CMS Wistrand has acted as legal advisor to Chordate Medical Holding AB (publ) in connection with the company’s rights issue of units, consisting of ordinary shares and preference shares, amounting to approximately SEK 22.2 million.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. Chordate Medical Holding AB (publ) is listed on Nasdaq First North Growth Market.
CMS Wistrand’s team mainly consisted of Niklas Larsson (responsible partner), Sebastian Petersen (senior associate) and Emelie Johannesson (associate).
